Antioxidant activity of carvedilol in cardiovascular disease

Journal of Hypertension

Volumn 25, Issue 4, 2007, Pages 731-741

  Dandona, Paresh ^a   Ghanim, Husam ^a   Brooks, David P ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Antioxidant; Carvedilol; Hypertension; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CELIPROLOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUTATHIONE; INSULIN; LABETALOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NADOLOL; NEBIVOLOL; PINDOLOL; PROPRANOLOL; REACTIVE OXYGEN METABOLITE; SB 211475; SCAVENGER; TRANSCRIPTION FACTOR; TROGLITAZONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; IN VIVO STUDY; INFLAMMATION; KIDNEY DISEASE; LIPID PEROXIDATION; LIPOPHILICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MYOCARDIAL DISEASE; MYOCARDITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; REPERFUSION INJURY; REVIEW; TREATMENT OUTCOME;

EID: 33947111435     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280127948     Document Type: Review

References (84)

1. Byrne JA, Grieve DJ, Cave AC, Shah AM. Oxidative stress and heart failure. Arch Mal Coeur Vaiss 2003; 96:214-221.
2. Ungvari Z, Gupte SA, Recchia FA, Batkai S, Pacher P. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005; 3:221-229.
3. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87:840-844.
4. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann Intern Med 1995; 123:860-872.
5. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003; 361:2017-2023.
6. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005; 293:1338-1347.
7. Arumanayagam M, Chan S, Tong S, Sanderson JE. Antioxidant properties of carvedilol and metoprolol in heart failure: a double-blind randomized controlled trial. J Cardiovasc Pharmacol 2001; 37:48-54.
8. Book WM. Carvedilol: a nonselective beta blocking agent with antioxidant properties. Congest Heart Fail 2002; 8:173-177; 190.
9. Maggi E, Marchesi E, Covini D, Negro C, Perani G, Bellomo G. Protective effects of carvedilol, a vasodilating beta-adrenoceptor blocker, against in vivo low density lipoprotein oxidation in essential hypertension. J Cardiovasc Pharmacol 1996; 27:532-538.
10. Ruffolo RR Jr, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovasc Drugs Ther 1997; 11 (Suppl 1):247-256.
11. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, et al. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263:92-98.
12. Dandona P, Karne R, Ghanim H, Hamouda W, Aljada A, Magsino CHJ. Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000; 101:122-124.
13. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004; 116:460-465.
14. Dandona P, Dhindsa S, Aijada A, Chaudhuri A. Classical anti-oxidants (scavengers) versus biological anti-oxidants (suppressors of ROS generation): a novel way to explain the anti-oxidant paradox. Metab Syndr Relat Disord 2005; 2:155-159.
15. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362:7-13.
16. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-2236.
17. Torp-Pedersen C. The effect of metoprolol and carvedilol on cause-specific mortality in chronic heart failure patients. The Carvedilol or Metoprolol European Trial. Am Heart J 2005; 149:370-376.
18. Gao F, Chen J, Lopez BL, Christopher TA, Gu J, Lysko P, et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol 2000; 406:109-116.
19. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31:1352-1356.
20. Lee J, Lee M, Kim JW, Jang JG, Choi YS, Cheong SS. Carvedilol reduces serum concentration of DNA-damage biomarker 8-hydroxydeoxyguanosine in human hypertension. Presented at the 53rd American College of Cardiology Annual Scientific Session; March 9, 2004; New Orleans, Louisianna, USA.
21. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111:1448-1454.
22. Feuerstein G, Yue TL, Ma X, Ruffolo RR. Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998; 41 (Suppl 1):17-24.
23. Feuerstein GZ, Bril A, Ruffolo RR Jr. Protective effects of carvedilol in the myocardium. Am J Cardiol 1997; 80:41L-45L.
24. Sorescu D, Griendling KK. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 2002; 8:132-140.
25. Ide T, Tsutsui H, Kinugawa S, Utsumi H, Kang D, Hattori N, et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999; 85:357-363.
26. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999; 85:437-445.
27. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104:2407-2411.
28. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002; 40:477-484.
29. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003; 41:2164-2171.
30. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 2000; 86:E85-E90.
31. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002; 105:2867-2871.
32. Hornig B, Arakawa N, Kohler C, Drexler H. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 97:363-368.
33. 2+-ATPase 2 gene transcription through modification of Sp1 binding. Biochem Biophys Res Commun 2005; 328:116-124.
34. Flesch M, Maack C, Cremers B, Baumer AT, Sudkamp M, Bohm M. Effect of beta-blockers on free radical-induced cardiac contractile dysfunction. Circulation 1999; 100:346-353.
35. Ruffolo RR, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharmacol 1998; 32 (Suppl 1):S22-S30.
36. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999; 99:2934-2941.
37. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996; 28:506-514.
38. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000; 87:392-398.
39. Li PF, Dietz R, von Harsdorf R. Superoxide induces apoptosis in cardiomyocytes, but proliferation and expression of transforming growth factor-beta1 in cardiac fibroblasts. FEBS Lett 1999; 448:206-210.
40. Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 2001; 19:152-171.
41. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320:915-924.
42. Donetti E, Soma MR, Barberi L, Paoletti R, Fumagalli R, Roma P, et al. Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits. Atherosclerosis 1998; 141:45-51.
43. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61:186-194.
44. Ueno Y, Kizaki M, Nakagiri R, Kamiya T, Sumi H, Osawa T. Dietary glutathione protects rats from diabetic nephropathy and neuropathy. J Nutr 2002; 132:897-900.
45. Raats CJ, Bakker MA, van den Born J, Berden JH. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272:26734-26741.
46. Mehrotra S, Ling KL, Bekele Y, Gerbino E, Earle KA. Lipid hydroperoxide and markers of renal disease susceptibility in African-Caribbean and Caucasian patients with Type 2 diabetes mellitus. Diabet Med 2001; 18:109-115.
47. Giner V, Tormos C, Chaves FJ, Saez G, Redon J. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 2004; 255:588-594.
48. Baylis C, Qiu C. Importance of nitric oxide in the control of renal hemodynamics. Kidney Int 1996; 49:1727-1731.
49. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357:1385-1390.
50. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-1355.
51. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651-1658.
52. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
53. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
54. Ruffolo RR, Feuerstein GZ. Carvedilol: preclinical profile and mechanisms of action in preventing the progression of congestive heart failure. Eur Heart J 1998; 19 (Suppl B):B19-B24.
55. Noguchi N, Nishino K, Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem Pharmacol 2000; 59:1069-1076.
56. Feuerstein GZ, Ruffolo RR Jr. Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 1995; 16 (Suppl F):38-42.
57. Feuerstein G, Liu GL, Yue TL, Cheng HY, Hieble JP, Arch JR, et al. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. Eur J Pharmacol 1998; 351:341-350.
58. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000; 36:276-281.
59. Lysko PG, Webb CL, Gu JL, Ohlstein EH, Ruffolo RR Jr, Yue TL. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol 2000; 36:277-281.
60. Yuan Z, Shioji K, Nimata M, Kishimoto C. Cardioprotective effects of carvedilol on acute autoimmune myocarditis. Mol Cell Biochem 2004; 259:223-227.
61. Kametani R, Miura T, Shibuya M, Iwamoto K, Tan H, Wang R, et al. The distinct effect of carvedilol and metoprolol on the mitochondrial superoxide production under calcium overload of myocardium. Poster presented at the American College of Cardiology 54th Annual Session; 8 March 2005; Orlando, Florida. J Am Coll Cardiol 2005; 45 (Suppl A):166A.
62. Matsui H, Morishima I, Numaguchi Y, Toki Y, Okumura K, Hayakawa T. Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sci 1999; 65:1265-1274.
63. Oliveira PJ, Bjork JA, Santos MS, Leino RL, Froberg MK, Moreno AJ, et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity. Toxicol Appl Pharmacol 2004; 200:159-168.
64. Romeo F, Li D, Shi M, Mehta JL. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res 2000; 45:788-794.
65. Yue TL, Ma XL, Wang X, Romanic AM, Liu GL, Louden C, et al. Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol. Circ Res 1998; 82:166-174.
66. Brunvand H, Liu G, Ma XL, Yue TL, Ruffolo RR Jr, Feuerstein GZ. SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits. Eur J Pharmacol 1998; 356:193-198.
67. Yang SP, Ho LJ, Lin YL, Cheng SM, Tsao TP, Chang DM, et al. Carvedilol, a new antioxidative beta-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-kappaB activity. Cardiovasc Res 2003; 59:776-787.
68. Cheng SM, Yang SP, Ho LJ, Tsao TP, Chang DM, Lai JH. Carvedilol modulates in-vitro granulocyte-macrophage colony-stimulating factor-induced interleukin-10 production in U937 cells and human monocytes. Immunol Invest 2003; 32:43-58.
69. Kim MS, Ha H, Kim YS, Park J, Kim H, Seo J, et al. Effect of carvedilol alone or in the presence of cyclosporine on the migration of vascular smooth muscle cell of rat. Transplant Proc 2003; 35:189-190.
70. Hata I, Kaji M, Hirano S, Shigematsu Y, Tsukahara H, Mayumi M. Urinary oxidative stress markers in young patients with type 1 diabetes. Pediatr Int 2006; 48:58-61.
71. Leinonen J, Lehtimaki T, Toyokuni S, Okada K, Tanaka T, Hiai H, et al. New biomarker evidence of oxidative DNA damage in patients with non-insulindependent diabetes mellitus. FEBS Lett 1997; 417:150-152.
72. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in noninsulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126:955-959.
73. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999; 99:2645-2651.
74. Chin BS, Gibbs CR, Blann AD, Lip GY. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in lowering chf oxidant stress: implications for beta blocker selection. Clin Sci (Lond) 2003; 105:507-512.
75. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12:212-221.
76. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004; 116:460-465.
77. Dandona P, Ghanim H, Sia CL, Viswanathan B, Chaudhuri A, Mohanty P. Carvedilol exerts a potent anti-inflammatory effect. Abstract presented at the 66th Annual Scientific Sessions of the American Diabetes Association, 9-13 June 2005; Washington, DC.
78. Magsino CH Jr, Hamouda W, Bapna V, Ghanim H, bu-Reish IA, Aljada A, et al. Nadolol inhibits reactive oxygen species generation by leukocytes and linoleic acid oxidation. Am J Cardiol 2000; 86:443-448.
79. Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, et al. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003; 23:615-621.
80. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press Suppl 2004; 1:2-16.
81. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86:3257-3265.
82. Garg R, Kumbkarni Y, Aljada A, Mohanty P, Ghanim H, Hamouda W, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 2000; 36:430-435.
83. Flather MD, Shibata MC, Coats AJ, van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26:215-225.
84. Veverka A, Nuzum DS, Jolly JL. Nebivolol: a third-generation beta-adrenergic blocker. Ann Pharmacother 2006; 40:1353-1360.